Search

Protocol for Pertussis Immunisation and Food Allergy (PIFA): a case-control study of the association between pertussis vaccination in infancy

We therefore speculate that removal of wP from the vaccine schedule contributed to the observed rise in IgE-mediated food allergy among Australian infants

Effects of maternal dietary egg intake during early lactation on human milk ovalbumin concentration: A randomized controlled trial

Increased maternal egg ingestion is associated with increased breastmilk ovalbumin, and markers of immune tolerance in infants

Consensus of stakeholders on precautionary allergen labelling: A report from the Centre for Food and Allergy Research

Precautionary allergen labelling is the main tool available to indicate safety levels for food-allergic consumers with regard to potential allergens

Epigenetic modifications: Mechanisms of disease and biomarkers of food allergy

The rise in IgE-mediated food allergy in recent times is the likely result of gene-environment interactions mediated via epigenetic pathways.

The gut microbiota and inflammatory noncommunicable diseases: Associations and potentials for gut microbiota therapies

This article discusses the relationships between gut colonization & inflammatory noncommunicable diseases, in regards to their treatment and prevention.

In-utero exposures and the evolving epidemiology of paediatric allergy

This paper discusses the rising prevalence of allergic disease in children. This review article considers recent findings in the field of paediatric immune...

A newborn's perspective on immune responses to food

In this review, we will highlight infants' immune responses to food, emphasizing the unique aspects of early-life immunity and the critical role of breast milk as a food dedicated to infants. Infants are susceptible to inflammatory responses rather than immune tolerance at the mucosal and skin barriers, necessitating strategies to promote oral tolerance that consider this susceptibility. 

Two-year post-treatment outcomes following peanut oral immunotherapy in the Probiotic and Peanut Oral Immunotherapy-003 Long-Term (PPOIT-003LT) study

Few studies have examined long-term outcomes following oral immunotherapy; none have examined long-term risks and benefits associated with distinct clinical outcomes (desensitization, remission).

Allergen Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years

Remission is the desired outcome following OIT as it allows individuals to discontinue treatment and eat the allergen freely. Early initiation of OIT in infants and toddlers has been embraced as an approach to increase the likelihood of remission. However, there is no high-quality evidence supporting younger age as an independent factor driving remission; available studies are limited by small samples of younger subjects and lack of adjustment for confounding covariates, particularly peanut-specific IgE (sIgE) levels which is closely cor

Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program

Peanut allergy is the most common food allergy in Australian school-aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease-modifying treatment for food allergy, is limited in many regions of the world, including Australia.